Metastatic uveal melanoma therapy: Current options

International Ophthalmology Clinics

Volumn 46, Issue 1, 2006, Pages 151-166

  Bedikian, Agop Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CEPHALOSPORIN; CISPLATIN; DACARBAZINE; DACTINOMYCIN; FOTEMUSTINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERFERON; INTERLEUKIN 2; IODINATED POPPYSEED OIL; LIVER ENZYME; LOMUSTINE; MELANOMA VACCINE; MELPHALAN; NARCOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TAMOXIFEN; TREOSULFAN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE SULFATE;

ABDOMINAL DISCOMFORT; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; ENUCLEATION; ENZYME BLOOD LEVEL; FEVER; HEMOFILTRATION; HEPATIC ARTERY; HUMAN; HYPERTHERMIC THERAPY; LIVER ABSCESS; LIVER METASTASIS; LIVER PERFUSION; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROTOXICITY; PARALYTIC ILEUS; POSTOPERATIVE CARE; POSTOPERATIVE NAUSEA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SEPTICEMIA; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UVEA MELANOMA; MELANOMA; METASTASIS; METHODOLOGY; PATHOLOGY; UVEA TUMOR;

COMBINED MODALITY THERAPY; HUMANS; MELANOMA; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 33644873740     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000195852.08453.de     Document Type: Review

References (63)

1. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651-4659.
2. Bedikian AY, Kantarjian H, Young SE. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74:574-577.
3. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
4. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389.
5. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100:122-129.
6. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219-2223.
7. Curley SA, Cusack JC, Tanabe KK, et al. Advances in the treatment of liver tumors. Curr Probl Surg. 2002;39:449-571.
8. Curley SA, Marra P, Beaty K, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004;239:450-458.
9. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 2004;11:290-297.
10. Fournier GA, Albert DM, Arrigg CA, et al. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol. 1984;102:80-82.
11. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89:1561-1568.
12. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma, indications and results. Cancer. 1985;56:1222-1230.
13. Wood TF, DiFronzo LA, Rose PM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol. 2001;8:658-662.
14. Hemming AW, Sielaff TD, Gallinger S, et al. Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl. 2000;6:97-101.
15. Gunduz K, Shields JA, Shields CL, et al. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol. 1998;125:407-409.
16. Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998;24:127-130.
17. Leyvraz S. Intra-arterial fotemustine for the treatment of liver metastases from uveal melanoma. Proceedings of Perspectives in Melanoma VII; 2004:111-115.
18. Camp R, Lind DS, Hemming AW. Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma. J Hepatobiliary Pancreat Surg. 2002;9:519-521.
19. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230:1-8.
20. Goldberg SN, Gazelle SG, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174:323-331.
21. rd. Radiofrequency ablation of liver: current status. AJR Am J Roentgenol. 2001;176:3-16.
22. Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000;7:593-600.
23. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist. 2001;6:24-33.
24. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Results in 123 patients. Ann Surg 1999;230(1):1-7.
25. Elias D, Baton O, Sideris L, et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol. 2004;11:500-505.
26. Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10:1059-1069.
27. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343-6349.
28. PingPank JF. Hyperthermic isolated hepatic perfusion (IHP) using melphalan for patients with ocular melanoma metastatic to the liver. Proceedings of Perspectives in Melanoma VII; 2004:117-125.
29. Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67-72.
30. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974-976.
31. Bedikian AY, McIntyre S, Hodges C, et al. Treatment of metastatic uveal and conjunctional melanoma. In: Gershenwald JE, ed. New York: Spring-Verlag. In press.
32. Feun LG, Reddy KR, Yrzarry JM, et al. Phase I hepatic chemoembolization trial with cisplatin and lipiodol [Abstract]. Proc Am Assoc Cancer Res. 1992;33:230, A-1376.
33. Sato T, Nathan FE, Berd D, et al. Lack of effect from chemoembolization for liver metastasis from uveal melanoma [Abstract]. Proc Am Soc Clin Oncol. 1995;14:415.
34. Patel K, Sullivan K, Aoyama T, et al. Hepatic artery chemoembolization (HAC) with BCNU for treatment of metastatic uveal melanoma. Proc Am Soc Clin Oncol. 2001;20:356a, #1421.
35. Sato K. Locoregional immuno(bio)therapy for liver metastases. Semin Oncol. 2002;29:160-167.
36. Sato T, Sullivan KL, Eschelman DJ, et al. Immunoembolization of malignant liver tumors with granulocyte/macrophage colony stimulating factor (GM-CSF) and ethiodized oil followed by gelatin sponge pledget: The final result of phase I/II study. Proc Am Soc Clin Oncol 2005;23:1695, 2514.
37. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha and interleukin-2. Br J Cancer. 2002;87:840-845.
38. Cantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori. 1994;80:37-39.
39. El-Kassas H, Shipe-Spotloe J, Gooding S, et al. A phase I trial of intra-arterial cisplatin (CDDP) with or without embolic occlusion (EO) of the hepatic artery in metastatic ocular melanoma (OM). Proc Am Soc Clin Oncol. 1995;14:518, #1331.
40. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:107-108.
41. Katato K, Liu PY, Sondak V, et al. Survival and response to treatment in patients with metastatic melanoma from intraocular primaries on SWOG studies [Abstract]. Proc Am Soc Clin Oncol. 1995;14:410.
42. Nathan FE, Sato T, Hart E, et al. Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma. Proc Am Soc Clin Oncol. 1994;13:394.
43. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992;10:1919-1926.
44. Nathan FE, Berd D, Sato T, et al. BOLD+interferon in treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16:201-208.
45. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366-2372.
46. Kivela T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:1115-1120.
47. Myatt N, Cree IA, Kurbacher CM, et al. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs. 1997;8:756-762.
48. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487-1493.
49. Corrie PG, Bulusu R, Mayer A, et al. Phase I study of gemcitabine and treosulfan in patients with metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol. 2002;21:80b, #2134.
50. Pfohler C, Cree IA, Ughurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs. 2003;14:337-340.
51. Kielholz U, Schuster R, Schmittel A, et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumors. Eur J Cancer. 2004;40:2047-2052.
52. Terheyden P, Brocker EB, Becker JC. Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol. 2004;130:395-399.
53. De Waard-Siebinga I, Creyghton WM, Kool J, et al. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol. 1995;79:847-855.
54. Soni S, Lee DS, DiVito J Jr, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol. 2002;24:488-491.
55. Minor DR, Cohen RJ, West W, et al. 5-year survival of an ocular melanoma patient with hepatic metastases treated with interleukin-2 (IL-2), LAK, & interferon [Abstract]. Proc Am Soc Clin Oncol. 1994;13:400.
56. Agarwala SS. Interleukin-2 plus histamine for metastatic uveal melanoma. Proceedings of Perspectives in Melanoma VII; 2004:103-104.
57. Maxim Pharmaceuticals to close treatment protocol and withdraw NDA for advanced malignant melanoma. Available at: http://investors.maxim.com/ releaseDetail.cfm?ReleaseID=146969. Accessed July 2, 2005.
58. Dorval T, Fridman WH, Mathiot C, et al. Interleukin-2 therapy for metastatic uveal melanoma [Letter]. Eur J Cancer. 1992;28A:2087.
59. Feun LG, Mazumder A, Marini A, et al. Pilot study of the initiation of an autoimmune reaction to tumor in melanoma patients by cyclosporine A, alpha interferon and interleukin0-2 following chemotherapy with BCNU, DTIC, cisplatin and tamoxifen. Proc Am Soc Clin Oncol. 2001;20:359a, #1431.
60. Keilholz U, Scheibenbogen C, Brado M, et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer. 1994;30A:103-105.
61. Terheyden P, Kampgen E, Runger TM, et al. Immunotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature. Hautarzt. 1998;49:770-773.
62. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840-845.
63. Proebstle TM, Scheibenbogen C, Sterry W, et al. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer. 1996;32A:1530-1533.